Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 14/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850827 | 0.88 | CACNA1H (0.45) | CACNA1HCACNA1CCACNA1BCACNA1GADORA1 | |
| SCHEMBL15850767 | 0.85 | CACNA1H (0.49) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL12495908 | 0.84 | CACNA1H (0.42) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15843980 | 0.84 | CACNA1H (0.56) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15852950 | 0.84 | CACNA1H (0.40) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15844215 | 0.84 | CACNA1H (0.46) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15844312 | 0.84 | CACNA1B (0.43) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15844092 | 0.83 | CACNA1H (0.44) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| Hydrochloric Acid SCHEMBL15844172 | 0.83 | CACNA1H (0.55) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL10284965 | 0.83 | GAA (0.47) | GAAHTTADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | CACNA1H 67/4885CACNA1C 48/4885CACNA1B 17/4885 |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | CACNA1H 4663/4885CACNA1C 3975/4885CACNA1B 4501/4885 |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CACNA1H 67/4885CACNA1C 48/4885CACNA1B 17/4885 |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | CACNA1H 66/4885CACNA1C 48/4885CACNA1B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.